Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)

Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)

There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitonea...

Full description

Bibliographic Details
Main Authors: Falla-Zuniga Luis Felipe, Sardi Armando, King Mary Caitlin, Lopez-Ramirez Felipe, Barakat Philipp, Nieroda Carol, Diaz-Montes Teresa, Gushchin Vadim
Format: Article
Language:English
Published: De Gruyter 2023-12-01
Series:Pleura and Peritoneum
Subjects:
peritoneal neoplasms
cytoreduction surgical procedures
hyperthermic intraperitoneal chemotherapy
ovarian neoplasms
Online Access:https://doi.org/10.1515/pp-2023-0019
Description
Summary:There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an effective treatment for PM of non-gynecologic origin and, recently, epithelial ovarian cancer. We evaluated the feasibility of CRS/HIPEC in the management of PM from rare ovarian malignancies and report postoperative outcomes on these patients.
ISSN:2364-768X

Similar Items